Dev Drugs (India) Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 16-11-2024
- Paid Up Capital ₹ 1.60 M
as on 16-11-2024
- Company Age 28 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.95 Cr
as on 16-11-2024
- Revenue -43.04%
(FY 2023)
- Profit -185.76%
(FY 2023)
- Ebitda 80.96%
(FY 2023)
- Net Worth -17.50%
(FY 2023)
- Total Assets -4.74%
(FY 2023)
About Dev Drugs (India)
The Corporate was formerly known as Noni Gopal Infinlease Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.60 M.
The company currently has active open charges totaling ₹5.95 Cr.
Balbir Singh and Subrata Roy serve as directors at the Company.
- CIN/LLPIN
U65929DL1996PTC082829
- Company No.
082829
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Oct 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Dev Drugs (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Balbir Singh  | Director | 15-Sep-2020 | Current |
| Subrata Roy | Director | 14-Sep-2021 | Current |
Financial Performance and Corporate Structure Insights of Dev Drugs (India).
Dev Drugs (India) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 43.04% decrease. The company also saw a substantial fall in profitability, with a 185.76% decrease in profit. The company's net worth observed a substantial decline by a decrease of 17.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dev Drugs (India)?
In 2023, Dev Drugs (India) had a promoter holding of 93.76% and a public holding of 6.24%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 29 Mar 2023 | ₹2.65 Cr | Open |
Sidbi Creation Date: 30 Mar 2022 | ₹2.00 Cr | Open |
Sidbi Creation Date: 03 Nov 2020 | ₹1.30 Cr | Open |
How Many Employees Work at Dev Drugs (India)?
Dev Drugs (India) has a workforce of 7 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dev Drugs (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dev Drugs (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
